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Objective. To classify the infection risk of human papillomavirus (HPV) among human immunodeficiency virus- (HIV-) negative
men who have sex with men (MSM) using group-based trajectory modeling (GBTM). Methods. This study collected data on
demographic and sexual behavior characteristics by questionnaires at semiannual visits from March 1st, 2016 to December 31th,
2017. Researchers collected anal exfoliated cells to finish HPV testing and blood samples to finish HIV testing at baseline and
follow-up visits. Accumulative infection numbers of different types of HPV as the primary outcome and the follow-up visits as
the independent predicator to build a GBTM model. Results. There were 500 potentially eligible HIV-negative participants at
baseline, 361 (72.2%) of whom were included in this study after screening. Three trajectory groups were identified as the best-
fitted GBTM model. Trajectory 1, defined as decreased group (DG) accounted for 44.6% (161/361) of the sample, showed a
declining pattern with visits. Trajectory 2, defined as flat group (FG) accounted for 49.6% (179/361) of the sample, showed a flat
pattern with visits. Trajectory 3, regarded as the increased group (IG) accounted for 5.8% (21/361) of the sample, showed an
uptrend. Compared to the DG, risk factors for the FG included receptive anal intercourse (AOR, 2.24; 95% CI, 1.36-3.71),
occasional condom use in anal sex during the past six months (AOR, 1.90; 95% CI, 1.16-3.14), experience of transactional sex
with males in the past year (AOR, 3.60; 95% CI, 1.12-11.54), and substance use (AOR, 1.81; 95% CI, 1.08-3.04). Risk factors for
the IG included receptive anal intercourse (AOR, 2.81; 95% CI, 1.04-7.70), occasional condom use in anal sex during the past six
months (AOR, 3.93; 95% CI, 1.40-11.01), and history of other STIs (AOR, 5.72; 95% CI, 1.40-23.46). Conclusion. The MSM data
in this study showed three distinct developmental trajectories (DG, FG, and IG) of HPV infection among HIV-negative MSM,
with receptive anal intercourse and occasional condom use in anal sex during the past six months being the risk factors
associated with FG and IG.
1. Introduction
Human papillomavirus (HPV) infection is one of the most
common sexually transmitted infections (STIs) worldwide
[1] and is paramount importance due to its association with
anal, urethral, penile, and oropharyngeal cancers in males
[2]. Generally, MSM have a higher prevalence and incidence
of HPV. Recently, studies among HIV-negative MSM have
revealed that 48.2% were positive for at least one of the anal
HPV genotypes in Guangzhou, China [3], 51.8% in Urumqi,
Hindawi
BioMed Research International
Volume 2020, Article ID 8174983, 10 pages
https://doi.org/10.1155/2020/8174983
China [4], and 62.8% in three cities (Chengdu, Xian, and Tai-
yuan), China [5]. Besides, anal HPV infection was found in
59% of HIV-negative MSM in Bangkok, central Thailand
[6], and 40% (49/124) of all MSM were infected with at least
one anal HPV genotype in Moscow, Russia [7].
There were 180 HPV genotypes, of which more than 40
HPV genotypes infected human genital mucosa [8], such as
HPV6, HPV11, HPV16, and HPV18. An HPV infection sta-
tus can vary over time, for example, (1) the virus in previ-
ously infected individuals could clear off between follow-up
visits; (2) on the contrary, previously uninfected individuals
could become infected between follow-up visits; or (3) it is
possible for individuals who have been cleared off the virus
to become reinfected [9–11]. As such, HPV infection can be
characterized as of a transient or persistent nature [12]. Per-
sistent anal HPV infection, particularly with carcinogenic
HPV types, is an important risk factor for the development
of anal cancer [13]. Thus, investigation of HPV infection risk
for individuals based solely on the primary test result would
only provide limited insights about changes in infection
trends over time, and as such a longitudinal investigation of
HPV infection could provide a better temporal resolution
on HPV infection trends.
Capturing diverse patterns of HPV infection types over
time poses a complex analytical challenge, in particular for
a subject infected with multiple HPV genotypes at the same
time. It was a huge amount of work to look at the trend of
HPV infection one by one. The GBTM can group the study
participants according to certain characteristics, which could
save time and simplify operations. “GBTM is a specialized
application of finite mixture modeling and is designed to
identify clusters of individuals following similar progressions
of some behavior or outcome over age or time” as suggested
by Nagin [14–16]. Although each person has unique charac-
teristics, some subjects may share one or several similar char-
acteristics that make it possible to classify them into different
categories or groups.
This method can be used to describe the course of many
phenomena, whether behavioral [17], biological [18], or
physical [19]. For the past few years, GBTM has been widely
used in the analysis of longitudinal data in medical research
[20] but by far there has been only one application of the
GBTM model in the analysis of MSM HIV data [21]. This
study is the first attempt to fully apply GBTM to the analysis
of MSM HPV infection data. Urumqi is the capital city of
Xinjiang, and its economic and cultural background are dif-
ferent from those of Chinese cities. There were no follow-
up studies on MSM HPV infection in this region, and this
study fills the gap on the topic issue in this region.
2. Materials and Methods
2.1. Study Population. An ongoing prospective study of HPV
infection among MSM was performed with the assistance of
two local nongovernmental organizations (NGO)—Tian-
shan Volunteers Workstation and Xinjiang Boys Rainbow
Dream Volunteers Service Center. The study exclusion cri-
teria included the following: (1) men younger than 18 or
older than 65 years of age; (2) men who reported they did
not have a history of anal sex with men in the past year; (3)
unwillingness to provide anal swab specimens for HPV test-
ing and blood for HIV testing at each study visit; (4) unwill-
ingness to complete a 63-item computer-assisted study
questionnaire on demographic, behavioral, and disease his-
tory; (5) prior HIV infection, treatment for anal cancer, anal
cytology or high-resolution anoscopy within 12 months prior
to enrollment. Informed consent was obtained from all par-
ticipants, and the study was granted an ethical approval by
the Xinjiang Medical University First Affiliated Hospital
Ethics Committee (ethical review number was 20160512-11).
The subjects were followed up at six-month intervals, and
the snowball sampling methods were used to recruit MSM in
Urumqi of Xinjiang, China, fromMarch 1st, 2016 to Decem-
ber 31th, 2017. We recruited a set number of eligible individ-
uals called “seeds,” who recruited (and were compensated for
recruiting) a set number of other eligible individuals from
among their network members [22]. Urumqi population
refers to the population living in Urumqi for a long time;
on the contrary, the non-Urumqi population refers to the
people who have long lived outside Urumqi.
A phased enrollment of participants was undertaken with
100 subjects entered into this study fromMarch 1st to March
31th, 2016 (they should participate in follow-up visits on
September 2016, March 2017, and September 2017), and
the remaining 400 subjects were enrolled from September
1st to December 31th, 2016 (they should participate in
follow-up visits on March 2017 to June 2017 and September
2017 to December 2017). A total of 5 participants tested
HIV-positive during follow-up and were subsequently
excluded from the study, and the other 134 individuals were
excluded from the study because they could not attend the
follow-up visits on time for two or more consecutive times.
Finally, from the remaining participants, 361 (72.2%) indi-
viduals with at least two visits were included in this study,
of which 327 individuals had information in HPV on three
visits, and 60 individuals had HPV information on four visits.
2.2. Specimen Collection and Laboratory Testing. A saline-
wetted swab was inserted 3-5 cm into participants’ anal canal
(between the anus and the anal canal dentate line) to collect
exfoliated cells. The anal epithelium was swabbed gently at
a 360° rotation for at least two minutes. The specimens were
placed into a standard transport medium (Hybribio Biotech
Limited Corporation, Chaozhou, China) and stored at
-20°C. Laboratory assessments were completed within a week
from specimen collection.
This study used Hybribio 37 HPV GenoArray Diagnostic
Kit (HPV 6, 11, 16, 18, 26, 31, 33-35, 39, 40, 42, 43-45, 51-59,
61, 66-73, and 81-84) and HybriMax (Hybribio Biotech Lim-
ited Corporation, Chaozhou, China) to distinguish for HPV
genotypes according to the experimental principle intro-
duced in a previous study [4]. Laboratory procedures under-
taken included DNA extraction, polymerase chain reaction
(PCR), and flow-through hybridization. The GenoArray Kit
included positive and negative controls, which were used in
every PCR analysis, as well as during the hybridization pro-
cess. Quality control was performed against 5% of the sam-
ples selected at random for retesting.
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Each participant’s HIV infection status was determined
by an enzyme immunoassay (Wantai Biological Pharmacy,
Beijing, China) and was confirmed by HIV-1/2 Western blot
assay (HIV Blot 2.2 WB; Genelabs Diagnostics, Singapore,
Singapore).
2.3. HPV Infection Classification. Participants were tested for
HPV at baseline and at six monthly intervals for 18 months
(up to 3 follow-up visits). Confirmation of HPV infection
was defined as a detection of one or more HPV types in the
collected specimen (i.e., HPV DNA positive genotyping).
Participants with an invalid HPV test were excluded from
the analysis. HPV infection was classified into six categories
[9–12] based on the combined detection results at baseline
and the three follow-up visits, as follows:
(1) Persistent Negative: HPV DNA test results, negative
at baseline and the 3 follow-up visits (-, -, -, -).
(2) Infection Clearance: HPV DNA test results, positive
at least in one of the first two visits (i.e., baseline or
first follow-up visit), but negative at the last two con-
secutive follow-up visits (-, +, -, -; or +, -, -, -; or +, +,
-, -).
(3) New Infection: HPV DNA test results, negative at
baseline and the first 2 follow-up visits, but positive
at the last follow-up visit (-, -, -, +).
(4) Continuous Positive Detection: HPV DNA test
results, negative or positive at baseline and the first
follow-up visit, but positive at the last two consecu-
tive follow-up visits (-, -, +, +; or -, +, +, +; or +, -,
+, +; or +, +, +, +). Since HPV persistent positive sta-
tus does not inform about HPV persistent infection,
we cannot distinguish between persistent infection
(by a given HPV type) and regular reinfection (by dif-
ferent types).
(5) Positive Detection Again: HPV DNA test results, neg-
ative at the second follow-up visit, but positive at the
last follow-up visit (-, +, -, +; or +, +, -, +; or +, -, -, +).
(6) Other Situations: HPV DNA test results, positive at
least in one of the first three visits (i.e., baseline or
first 2 follow-up visits), but negative at the last
follow-up visit (-, -, +, -; or -, +, +, -; or +, -, +, -; or
+, +, +, -). The number of the follow-up visits was
limited; therefore, it was not possible to determine
infection trends.
2.4. GBTM Establishment. Jones et al. successfully developed
GBTM methodology based on a semiparametric, group-
based modeling strategy and established through PROC
TRAJ, a SAS macro procedure [23, 24]. GBTM analysis was
conducted using SAS PROC TRAJ (SAS Institute, Inc.; Cary,
NC, USA) to identify subgroups; it was a Bayesian approach.
With SAS PROC TRAJ, the levels and shapes of trajectories
are determined by the model’s regression parameters, and
the maximum likelihood method was used for the estimation
of the model parameters. Technically, the model was a mix-
ture of probability distributions that were suitably specified
to describe the data to be analyzed. Therefore, the model
assumes that repeated observations on the same individual
are independent conditional on trajectory group, meaning
that the within-person correlation structure is explained
completely by the estimated trajectory curve for each per-
son’s group. The output of a GBTM includes estimated prob-
abilities of group membership for each individual and each
group and an estimated trajectory curve over time for each
group [25].
proc traj data=AR out=of outstat=os outplot=op;
id id;
var y1-y4;
indep t1-t4;
model zip;
min 0;
max 11;
ngroups 3;
order 3 3 3;
run;
The “y1-y4” were set as outcome variable (y), represent-
ing the accumulative infection numbers of different HPV
types in baseline and three follow-up visits. The diagnostic
kit used was capable of determining thirty-seven HPV types,
if the participants were tested for one of thirty-seven types,
y = 1, and if the participants were tested for two of thirty-
seven types, y = 2, and so forth. The “t1-t4” were set as the
independent variable (x), representing the baseline and three
follow-up visits. SAS PROC TRAJ has the capability of
modeling three different distributions (continuous, binary,
and count) [14–16]. In the current research, the Poisson
model was used to analyze the collected count data. However,
due to the large proportion of zero values present in the cur-
rent dataset, a Zero-Inflated Poisson (ZIP) model was used to
account for the fact. The “ngroups” is the model to be fitted:
“ngroups 1” stands for “one-trajectory model,” “ngroups 2”
for “two-trajectory model,” “ngroups 3” for “three-
trajectory model,” and “ngroups 4” for “four-trajectory
model.”
2.5. Model Evaluation. To determine the number of trajec-
tory groups present within our sample, we fit a series of
GBTM with 1 to 4 groups (an error was reported when the
groups are greater than 5). In selecting the appropriate num-
ber of trajectory groups, we considered the following criteria:
(1) Bayesian information criteria (BIC), as previously
reported, the largest BIC value indicates the best-fitting
model [14]; (2) the average posterior probability (AvePP),
reflected the posteriori probability of each individual classi-
fied to the corresponding subgroups, with values closer to 1
indexing greater precision, and the minimum threshold set
at 0.7 for individuals [23, 24]; (3) group size; (4) the useful-
ness of the number of groups in terms of the similarities/dif-
ferences in their trajectory shapes.
2.6. Statistical Analysis. Data entry was performed indepen-
dently by two staff members using the EpiData version 3.1
software (The Epi Data Association Odense, Denmark). Par-
ticipants who were grouped by GBTM defined as “expected,”
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and those who were grouped by researchers in this study
defined as “observed.” We used the following definitions to
group “observed”: (1) DG: participants who were HPV per-
sistent negative and infection clearance; (2) FG: participants
who were HPV continuously positive detection, new infec-
tion, positive detection again, and other situations, the HPV
DNA test results were 0 ≤ y ≤ 4 at baseline and three
follow-up visits, and the curve showed a flat trend; (3) IG:
participants who were HPV continuous positive detection,
the HPV DNA test results were 5 ≤ y ≤ 11 at baseline and
three follow-up visits, and the curve showed an increased
trend. Participants who were HPV other situations, the
HPV DNA test results were 5 ≤ y ≤ 11 at baseline and first 2
follow-up visits, but y = 0 at the last follow-up visits.
This study used SPSS 21.0 (SPSS Inc., Chicago, IL, USA)
for disposing and analyzing data. Demographic and sexual
behavior variables are presented as absolute numbers and
proportions or as median and range interquartile for each
category. Comparisons among different groups were con-
ducted with 2-sided Pearson chi-square test, Fisher’s exact
test, and nonparametric tests. Normality tests were per-
formed for continuous variables before conducting further
analyses. A multinomial logistic regression model was used
to explore risk factors associated with the FG (y = 2) and IG
(y = 3) groups compared to DG (y = 1). All variables with P
< 0:25 were included and adjusted in the multivariate
models. The significance level was set at α = 0:05.
3. Results
3.1. Model Selection. The BIC value was -1455.35, -1323.76,
-1311.32, and -1305.82 in one-trajectory model, two-trajec-
tory, three-trajectory model, and four-trajectory model sev-
erally, indicated a good data fit for four-trajectory model;
however, the trajectory 3 in four-trajectory model was sepa-
rated from trajectory 1 and trajectory 2, included individuals
with infection clearance, and showed a declining pattern with
visit as well as trajectory 1. Finally, we opted for the three-
trajectory model for simplicity, and the development trends
could display clearly. The AvePP assignment for each trajec-
tory in three-trajectory model was greater than 0.7, and the
three-trajectory model was judged to be adequate based on
the diagnostics (Table 1). Figures 1–4 showed the one-
trajectory model, two-trajectory model, three-trajectory
model, and four-trajectory model, respectively.
Trajectory 1 included 44.6% (161/361) participants who
were persistent negative (-, -, -, -) and infection clearance
(+, -, -, -). Trajectory 2 included 49.6% (179/361) participants
who mainly had a new infection (-, -, -, +), continuous posi-
tive detection (-, -, +, + or -, +, +, + or +, -, +, + or +, +, +, +),
positive detection again (-, +, -, + or +, +, -, + or +, -, -, +), and
other situations (-, -, +, - or -, +, +, - or +, +, +, -), 0 ≤ y ≤ 4.
Trajectory 3 included 5.8% (21/361) participants who were
continuous positive detection (-, -, +, + or -, +, +, + or +, -,
+, + or +, +, +, +), 5 ≤ y ≤ 11, and other situations (-, -, +, -
or -, +, +, -), 0 ≤ y ≤ 11 (up to 11 types of virus were detected
simultaneously). Based on the graphical presentation, trajec-
tory 1 showed a declining pattern with visit and was classed
as the DG; trajectory 2 showed a flat pattern and was classed
as the FG, and trajectory 3 showed an upward trend and was
classed as the IG (Figure 3).
Comparisons between expected and observed outcomes
amongst the three risk groups identified that 14 participants
grouped in trajectory 2 (FG) during modelling showed infec-
tion clearance (-, +, -, - or +, +, -, -), and as such based on
observed HPV infection classification results has to be
instead classified into trajectory 1 (DG). Similarly, 4 partici-
pants in the trajectory 2 (FG) with new infection (y ≥ 5)
should be classified into trajectory 3 (IG) (Table 2).
3.2. Demographic and Sexual Behavior Characteristics
between Different Groups. The percentage of participants
belonging to an ethnic minority for DG, FG, and IG was
5.0% (8/161), 12.3% (22/179), and 19.0% (4/21), respectively,
revealing a statistically significant difference (P = 0:014) of
the ethnic minority distribution between the three HPV risk
groups. Moreover, analysis of sexual behavior characteristics
showed that 24.8% (40/161), 39.7% (71/179), and 47.6%
(10/21) of participants primarily had receptive anal sex
(P = 0:005) in DG, FG group, and IG, respectively. In addi-
tion, the proportion of the population using condoms every
time during anal sex and as well as reporting having had
other STIs for DG, FG, and IG was 75.8% (122/161), 59.8%
(107/179), and 47.6% (10/21) (P = 0:001) and 5.6% (9/161),
8.4% (15/179), and 23.8% (5/21) (P = 0:024) severally
(Table 3).
3.3. Risk Factors. The DG was used as the reference group; a
multinomial logistic regression analysis showed that risk fac-
tors for the FG compared with the DG included receptive
anal intercourse (AOR, 2.24; 95% CI, 1.36-3.71), occasional
use of condoms in anal sex during past six months (AOR,
1.90; 95% CI, 1.16-3.14), experience of transactional sex with
males in the past year (AOR, 3.60; 95% CI, 1.12-11.54), and
substance use (AOR, 1.81; 95% CI, 1.08-3.04) (Table 4).
Identified risk factors for IG against DG included recep-
tive anal intercourse (AOR, 2.81; 95% CI, 1.04-7.70), occa-
sional use of condoms in anal sex during past six months
(AOR, 3.93; 95% CI, 1.40-11.01), and history of other STIs
(AOR, 5.72; 95% CI, 1.40-23.46) (Table 4).
4. Discussion
The persistent infection, clearance, and reinfection of HPV
involve a complex set of immune mechanisms, particularly
the multiple type infection of HPV at the same time. In this
study, the cumulative number of different types of HPV
infection was taken as the main study variable, because the
following speculation can be made according to the natural
history of HPV infection: if a subject was positive for the
HPV at each follow-up visit (regardless of which type of
HPV was positive), then during the long-term follow-up,
the subject may simultaneously develop persistent infection
of a particular type, new infection of another type, or reinfec-
tion of a particular type, and so on. These subjects are more
likely to develop certain HPV-related clinical symptoms in
the future than those who are persistent negative and clear
the infection.
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In recent years, GBTM has been widely used in the field
of medical research for noncommunicable diseases [14]. Suc-
cessful implementation of GBTM includes family income
trajectories with adiposity in adolescence [18], trajectories
of fiberoptic endoscopic evaluation of swallowing in dyspha-
gic patients [26], and trajectories of cognitive decline among
dementia patients [27]. GBTM also has been applied in the
analysis of infectious disease data, such as the case of Else-
nsohn and colleagues [20] who used data on CD4 T lympho-
cyte counts in patients with HIV receiving antiretroviral
treatment to build a GBTM, with an aim at potentially aiding
medical decisions. Nevertheless, GBTM has not been
employed for analysis of MSMHPV infection data; therefore,
this study constituted the first attempt to fully apply GBTM
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Figure 2: The development trends of HPV infection among 361
HIV-negative MSM in Urumqi, China, by two-trajectory model.
Table 1: Comparison of different HPV∗ trajectory models from GBTM∗ analysis among 361 HIV∗-negative MSM∗ in Urumqi, China.
BICa AvePPb
Members make up for the overall proportion [N (%)]
Trajectory 1 Trajectory 2 Trajectory 3 Trajectory 4
One-trajectory model -1455.35 1.000 361 (100.0) - - -
Two-trajectory model -1323.76 0.908 221 (61.2) 140 (38.8) - -
Three-trajectory model -1311.32 0.876 161 (44.6) 179 (49.6) 21 (5.8) -
Four-trajectory model -1305.82 0.854 151 (41.8) 167 (46.3) 22 (6.1) 21 (5.8)
When the number of subgroups ≥ 5, the BIC ≤ −1312:69. ∗MSM: men who have sex with men; HIV: human immunodeficiency virus; HPV: human
papillomavirus; GBTM: group-based trajectory modeling. aBIC: Bayesian information criteria, wherein the largest value indicates the best-fitting model.
bAvePP: average posterior probability, with values closer to 1 indexing greater precision, and the minimum threshold of this value was 0.7 for individuals.
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Figure 1: The development trends of HPV infection among 361
HIV-negative MSM in Urumqi, China, by one-trajectory model.
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Figure 3: The development trends of HPV infection among 361
HIV-negative MSM in Urumqi, China, by three-trajectory model.
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Figure 4: The development trends of HPV infection among 361
HIV-negative MSM in Urumqi, China, by four-trajectory model.
Table 2: Comparison of expected∗ and observed∗ outcomes in
three groups of HPV∗ infection as suggested by GBTM∗ among
361 HIV∗-negative MSM∗ in Urumqi, China.
Expected∗ Observed∗ χ2 P value
N % N %
Decreased group 161 44.6 175 48.5
1.884 0.390Flat group 179 49.6 161 44.6
Increased group 21 5.8 25 6.9
∗MSM: men who have sex with men; HIV: human immunodeficiency virus;
HPV: human papillomavirus; GBTM: group-based trajectory modeling;
expected outcomes: as suggested by GBTM; observed outcomes: as
suggested by HPV infection classification. Decreased group: trajectory 1;
flat group: trajectory 2; increased group: trajectory 3 in the GBTM.
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Table 3: Comparison of the demographic and the sex behavior characteristics between the three HPV∗ trend groups as suggested by GBTM∗
among 361 HIV∗−negative MSM∗ in Urumqi, China.
Total (N =361) Three HPV trend groups [N (%)] χ2 P valueDG (N =161) FG (N =179) IG (N =21)
Demographic characteristics
Age (years)
18~ 170 (47.1) 75 (46.6) 84 (46.9) 11 (52.4)
6.865 0.13830~ 129 (35.7) 66 (41.0) 58 (32.4) 5 (23.8)
40~ 62 (17.2) 20 (12.4) 37 (20.7) 5 (23.8)
Median (range) 30 (18-52) 30 (18-47) 30 (18-52) 29 (22-46)
City of residence
Urumqi 198 (54.8) 89 (55.3) 100 (55.9) 9 (42.9)
1.311 0.531
Non-Urumqi 163 (45.2) 72 (44.7) 79 (44.1) 12 (57.1)
Ethnicity
Han ethnicity 327 (91.0) 153 (95.0) 157 (87.7) 17 (81.0)
8.150 0.014
Minority ethnicity 34 (9.0) 8 (5.0) 22 (12.3) 4 (19.0)
Years of schoola
<12 66 (18.3) 25 (15.5) 35 (19.6) 6 (28.6)
1.847 0.39713–15 108 (29.9) 49 (30.4) 53 (29.6) 6 (28.6)
>16 187 (51.8) 87 (54.0) 91 (50.8) 9 (42.9)
Marital statusb
Unmarried 269 (74.5) 128 (79.5) 127 (70.9) 14 (66.7)
7.741 0.102Married 65 (18.0) 25 (15.5) 37 (20.7) 3 (14.3)
Divorced or widowed 27 (7.5) 8 (5.0) 15 (8.4) 4 (19.0)
Employment status
Employed 250 (86.5) 138 (85.7) 151 (84.4) 20 (95.2)
1.509 0.474
Unemployed 39 (13.5) 23 (14.4) 28 (15.6) 1(4.8)
Monthly income (yuan)a
≤1000 31 (8.6) 10 (6.2) 20 (11.2) 1 (4.8)
3.285 0.193
1001–5000 180 (49.8) 80 (49.7) 85 (47.5) 15 (71.4)
5001–9999 119 (33.0) 52 (32.3) 63 (35.2) 4 (19.0)
≥10000 31 (8.6) 19 (11.8) 11 (6.1) 1 (4.8)
Sex behavior characteristics
Age at sexual debut (years)a
<20 150 (41.6) 65 (40.4) 78 (43.6) 7 (33.3)
0.330 0.84820–24 146 (40.4) 67 (41.6) 68 (38.0) 11 (52.4)
>25 65 (18.0) 29 (18.0) 33 (18.4) 3 (14.3)
Median (range) 20 (13-35) 20 (13-33) 20 (13-35) 20 (15-29)
Self-reported sexual orientation
Homosexual 303 (83.9) 138 (85.7) 148 (82.7) 17 (81.0)
0.878 0.633
Heterosexual and other 58 (16.1) 23 (14.3) 31 (17.3) 4 (19.0)
Pattern of anal intercourse
Mainly insertive 240 (66.5) 121 (75.2) 108 (60.3) 11 (52.4)
10.491 0.005
Mainly receptive 121 (33.5) 40 (24.8) 71 (39.7) 10 (47.6)
Frequency of condom use for anal sex in the past 6 months
Sometimes 122 (33.8) 39 (24.2) 72 (40.2) 11 (52.4)
13.255 0.001
Always 239 (66.2) 122 (75.8) 107 (59.8) 10 (47.6)
Number of male anal sex partners in the past 6 months
≤2 283 (78.4) 132 (82.0) 136 (76.0) 15 (71.4)
2.608 0.258
≥3 78 (21.6) 29 (18.0) 43 (24.0) 6 (28.6)
Ever had sex with female in the past 6 months
No 320 (88.6) 142 (88.2) 159 (88.8) 19 (90.5)
0.071 0.963
Yes 41 (11.4) 19 (11.8) 20 (11.2) 2 (9.5)
Ever had transactional sex with man in the past year
No 341 (94.5) 157 (97.5) 164 (91.6) 20 (95.2)
5.686 0.052
Yes 20 (5.5) 4 (2.5) 15 (8.4) 1 (4.8)
Ever had circumcision surgery
No 228 (63.2) 101 (62.7) 114 (63.7) 13 (61.9)
0.091 0.984
Yes 133 (36.8) 60 (37.3) 65 (36.3) 8 (38.1)
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to the analysis of MSM HPV infection data. In the current
study, diagnostic statistics facilitated the selection of a model
with three trajectories, which could more clearly visualize the
development trends of HPV infection.
Trajectory 1 included 44.6% (161/361) participants who
were persistent negative or showing infection clearance and
showed a slightly declining trend in the number of infections;
this trajectory was regarded as the DG because the greatest
proportion of participants had asymptomatic transient infec-
tions [28, 29]. Giuliano et al. [12] reported that 66% and 90%
of HPV positive men are clear of HPV after 12 months and
24 months, respectively (the clearance of HPV is an autoim-
munity clearance). It is believed that individuals who clear off
an HPV infection may subsequently acquire natural immu-
nity [30]. In conclusion, we made trajectory 1 as low risk
group for HPV persistent infection.
Furthermore, trajectory 2 was characterized by 49.6%
(179/361) of participants; this trajectory was regarded as the
FG and showed a flat pattern in the number of infections.
Individuals with the continuous positive detection, positive
detection again, or other situations were assigned to the same
group (0 ≤ y ≤ 4), suggesting that may be there was a similarity
in HPV persistent infection risk. Once a previous HPV infec-
tion completely clears, current PCR-based assay methods can-
not distinguish whether reinfection with HPV is due to a
potential new acquisition or a reactivation of a previous virus
[31, 32]; therefore, individuals who were continuously positive
detection and positive detection again should be closely
observed because they may develop a persistent infection,
and persistent infection with high-risk HPV (HPV16 and
HPV18) would increase the risk of cancer. In addition, “Clear-
ance was defined as one positive test result for a specific HPV
type followed by two consecutive negative visits.” [33]. The
participants’ HPV DNA positive test results at the second
follow-up visit, but negative ones at the last follow-up visit
(-/+, -/+, +, -), those who may have cleared the virus or devel-
oped a reinfection in the next follow-up visit, and reinfection
may further increase the risk of a persistent infection. Taken
together, we hypothesized that participants in above condi-
tions were at moderate risk for HPV persistent infection.
Lastly, trajectory 3 included 5.8% (21/361) of participants
who displayed an ascending trend in number of infections,
and as such, this trajectory was defined as the IG; 19/21 par-
ticipants were continuous positive detection (5 ≤ y ≤ 11), and
2/21 participants were other situations. The HPV DNA test
results were 5 ≤ y ≤ 11 at baseline and first 2 follow-up visits,
but y = 0 at the last follow-up visits; they may develop HPV
reinfection at the next follow-up. They were detected multi-
ple HPV types at the same time, predicting a high risk of
HPV persistent infection.
In this study, we compared the FG and IG groups against
the DG in a multinomial logistic regression model and deter-
mined that receptive anal sex, occasional use of condoms
during anal intercourse, substance use, experience of transac-
tional sex with males, and history of other STIs were signifi-
cant risk factors of the occurrence of HPV. Donà et al. [29]
demonstrated that MSM who reported receptive anal sex
showed a higher incidence of infection by any HPV type
compared to those who did not engage in receptive anal sex
(HR, 2.65; 95% CI, 1.16-6.06). In addition, Winer et al. [34]
found that consistent condom use by their partner appeared
to reduce the risk of HPV infection. Furthermore, Yu et al.
[35] reported that “High rates of drug use, coupled with high
rates of ulcerative STIs such as HPV, suggest the potential for
rapid amplification of STIs/HIV risk.” Finally, a report by
Colón et al. [36] concluded that self-reported syphilis MSM
had a higher risk of high-risk HPV infection than nonre-
ported (OR, 4.00; 95% CI, 1.20-13.37).
Persistent HPV infection may be related to individual
immunity; immunization experiments are expensive, and
monitoring of each individual’s immunity perhaps is even
harder to accomplish. Grouping participants by GBTM and
focusing on the subgroup of an uptrend, such as trajectory
3 in this cohort study, could improve the cost-effectiveness
of immunization experiments. In summary, for disease pre-
vention and control, policymakers should formulate pro-
grams that favor the public macroscopically, for example,
vaccination strategies for MSM with high risk of HPV persis-
tent infection. HPV vaccines have only recently been mar-
keted in China and are mainly targeted at females. Unlike
men who have sex with women would benefit through herd
immunity from female-only vaccination strategies, HPV-
associated disease among MSM is unlikely to decline in
female-only vaccination settings [37]. To address this issue,
Table 3: Continued.
Total (N =361) Three HPV trend groups [N (%)] χ2 P valueDG (N =161) FG (N =179) IG (N =21)
Ever had other STIsc
No 332 (92.0) 152 (94.4) 164 (91.6) 16 (76.2)
6.976 0.024
Yes 29 (8.0) 9 (5.6) 15 (8.4) 5 (23.8)
Substance used
No 259 (71.7) 123 (76.4) 123 (68.7) 13 (61.9)
3.648 0.167
Yes 102 (28.3) 38 (23.6) 56 (31.3) 8 (38.1)
Ever obtained sex partner with man from the males public baths
No 296 (82.0) 138 (85.7) 142 (79.3) 16 (76.2)
3.044 0.223
Yes 65 (18.0) 23 (14.3) 37 (20.7) 5 (23.8)
∗MSM: men who have sex with men; HIV: human immunodeficiency virus; HPV: human papillomavirus; GBTM: group-based trajectory modeling. DG:
decreased group; FG: flat group; IG: increased group; the sample numbers (e.g., N = 161) are number of participants. aGrade data was tested by
nonparametric tests. bDivorced or widowed: two participants in the study were widowed. cOther STIs: candida albicans, syphilis, gonorrhea, human
herpesvirus, hepatitis B, etc. dSubstance use: marijuana, amyl nitrates, crack, other cocaine, and uppers.
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some scholars have been advocating for the promotion of
HPV vaccination in MSM [38].
The information on the behavioral characteristics of dif-
ferent development trend groups was conducive to screen the
high-risk infection individuals through the questionnaire
without laboratory test. For example, subjects who had
receptive anal intercourse, occasional use of condoms in anal
sex, experience of transactional sex, or substance use maybe
infectious ones; this hypothesis needs to be verified by a long
study. In ethical terms, health interventions should be
launched for all categories of HPV infection, whether it is
persistent positive, new infection, or other situations. Fortu-
nately, the GBTM can group the study participants according
to certain characteristics before the preventive intervention,
which could save time, simplify operations, play a positive
role in the screening of risk groups, and achieve precision
prevention.
Since this was an exploratory study, a sample size calcu-
lation was not undertaken. Properly powered studies in the
future would be more advantageous. The study is based on
a 1.5-year follow-up data, and the robustness of the GBTM
results for long-term studies needs to be verified. Further-
more, since the nonprobabilistic sampling method was used
in this study, the extrapolation of the research results should
be made with caution. Lastly, the PCR-based assay methods
in this study cannot distinguish whether infection with
HPV is prevalence or incidence; maybe there were
prevalence-incidence biases.
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Table 4: The results of risk factors of flat group and increased group for HPV∗ infection among 361 HIV∗-negative MSM∗ in Urumqi, China:
a multinomial logistic model analysis.
Flat group Increased group
AOR∗ (95% CI∗) P value AOR (95% CI) P value
Age (years)
18~ Ref. Ref.
30~ 0.77 (0.45-1.31) 0.333 0.40 (0.12-1.38) 0.148
40~ 1.44 (0.61-3.38) 0.405 0.96 (0.17-5.41) 0.961
Ethnicity
Han ethnicity Ref. Ref.
Minority ethnicity 2.38 (0.99-5.71) 0.052 2.91 (0.70-12.10) 0.142
Marriage status
Unmarried Ref. Ref.
Married 1.41 (0.67-2.96) 0.363 1.42 (0.27-7.32) 0.679
Divorced or widoweda 1.58 (0.55-4.50) 0.393 5.50 (0.94-32.20) 0.059
Pattern of anal intercourse
Mainly insertive Ref. Ref.
Mainly receptive 2.24 (1.36-3.71) 0.002 2.81 (1.04-7.70) 0.041
Frequency of condom use for anal sex in the past 6 months
Always Ref. Ref.
Sometimes 1.90 (1.16-3.14) 0.011 3.93 (1.40-11.01) 0.009
Ever had transactional sex with man in the past year
No Ref. Ref.
Yes 3.60 (1.12-11.54) 0.031 2.09 (0.20-21.38) 0.535
Ever had other STIsb
No Ref. Ref.
Yes 1.36 (0.53-3.48) 0.525 5.72 (1.40-23.46) 0.015
Substance usec
No Ref. Ref.
Yes 1.81 (1.08-3.04) 0.025 2.69 (0.94-7.74) 0.066
Ever obtained sex partner with man from the males public baths
No Ref. Ref.
Yes 1.17 (0.62-2.22) 0.634 1.02 (0.28-3.74) 0.973
Reference group: decreased group. ∗MSM: men who have sex with men; HIV: human immunodeficiency virus; HPV: human papillomavirus; AOR: adjusted
odds ratio; CI: confidence interval. aDivorced or widowed: two participants in the study were widowed. bSubstance use: marijuana, amyl nitrates, crack,
other cocaine, and uppers. cOther STIs: candida albicans, syphilis, gonorrhea, human herpesvirus, hepatitis B, etc.
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